caa a22 4500 475819012 CHVBK 20180406123817.0 cr unu---uuuuu 170329e20000501xx s 000 0 eng 10.1007/s002280050738 doi (NATIONALLICENCE)springer-10.1007/s002280050738 Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability [Elektronische Daten] [R. Lagnaoui, N. Moore, J. Fach, M. Longy-Boursier, B. Bégaud] Objective: Adverse drug reactions (ADRs) are a major cause of hospital admission and in-hospital morbidity. Departments of internal medicine are at the forefront of this problem. To increase the knowledge base, we did a study of the frequency, hazard function, avoidability, and cost of ADRs as a cause for admission in internal medicine, or when occurring after admission. Methods: This prospective cohort study was based on all admissions to an internal medicine unit over a 4-month period. Patients were intensively followed in order to assess any ADR occurring during the hospital stay. Causality, direct costs, and preventability were assessed. Results: Of 444 admissions (2569 patient-days), 156 ADRs occurred in 116 patients (26.1% of all admissions); 95 (21.4%) of these had ADRs at admission, which were the reason for admission in 32 (7.2%). Twenty-one patients (4.7%) presented with 26 ADRs during hospitalization. The in-hospital ADR incidence rate was 10.1 per 1000 patient-days. The cost of ADRs leading to hospitalization was estimated at Euro 11,357 per hospital bed per year. Eighty percent of ADRs could be considered preventable. Conclusion: ADRs in hospitalized patients are common and often preventable. Since most ADRs occurred before admission, prevention strategies should preferentially target primary health care providers. Springer-Verlag Berlin Heidelberg, 2000 Key words Adverse drug reactions nationallicence Hospital nationallicence Costs nationallicence Lagnaoui R. Department of Pharmacology, Université Victor Segalen, Zone Nord Bat 1A, F-33076 Bordeaux, France e-mail: rajaa.lagnaoui@pharmaco.u-bordeaux2.fr Tel.: +33-5-57571561; Fax: +33-5-56245889, FR aut Moore N. Department of Pharmacology, Université Victor Segalen, Zone Nord Bat 1A, F-33076 Bordeaux, France e-mail: rajaa.lagnaoui@pharmaco.u-bordeaux2.fr Tel.: +33-5-57571561; Fax: +33-5-56245889, FR aut Fach J. Department of Internal Medicine, Hôpital Saint-André, CHU Bordeaux, France, FR aut Longy-Boursier M. Department of Internal Medicine, Hôpital Saint-André, CHU Bordeaux, France, FR aut Bégaud B. Department of Pharmacology, Université Victor Segalen, Zone Nord Bat 1A, F-33076 Bordeaux, France e-mail: rajaa.lagnaoui@pharmaco.u-bordeaux2.fr Tel.: +33-5-57571561; Fax: +33-5-56245889, FR aut https://doi.org/10.1007/s002280050738 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050738 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lagnaoui R. Department of Pharmacology, Université Victor Segalen, Zone Nord Bat 1A, F-33076 Bordeaux, France e-mail: rajaa.lagnaoui@pharmaco.u-bordeaux2.fr Tel.: +33-5-57571561; Fax: +33-5-56245889, FR aut NATIONALLICENCE 700 1- Moore N. Department of Pharmacology, Université Victor Segalen, Zone Nord Bat 1A, F-33076 Bordeaux, France e-mail: rajaa.lagnaoui@pharmaco.u-bordeaux2.fr Tel.: +33-5-57571561; Fax: +33-5-56245889, FR aut NATIONALLICENCE 700 1- Fach J. Department of Internal Medicine, Hôpital Saint-André, CHU Bordeaux, France, FR aut NATIONALLICENCE 700 1- Longy-Boursier M. Department of Internal Medicine, Hôpital Saint-André, CHU Bordeaux, France, FR aut NATIONALLICENCE 700 1- Bégaud B. Department of Pharmacology, Université Victor Segalen, Zone Nord Bat 1A, F-33076 Bordeaux, France e-mail: rajaa.lagnaoui@pharmaco.u-bordeaux2.fr Tel.: +33-5-57571561; Fax: +33-5-56245889, FR aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer